[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596312":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":24,"locations":12,"responsibleParty":30,"collaborators":34,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":12,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":60,"whyStopped":12,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":12},{"fullName":5,"class":6},"Universiti Sains Malaysia","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","NO_INTERVENTION","Patients randomized to the control group will receive standard care provided in a diabetes excellence center, including nurse assessment, physician assessment, and care provision by a multidisciplinary team. They will also visit the hospital pharmacy to fill their prescriptions without further clinical pharmacist intervention. However, there will be no restriction on contacting the clinical pharmacist for advice.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Interventional Group (PharmaTE group)","EXPERIMENTAL","In addition to standard care, patients in the PharmaTE trial interventional group will receive tele-education led by a clinical pharmacist who has completed a training course and is certified as a diabetes educator. The tele-education program is comprised of five individualized educational sessions, each lasting approximately 20-30minutes and held at two-month intervals. These sessions are conducted via Zoom or telephone based on patient preference. Before the beginning of each session, participants will receive a reminder message along with the Zoom meeting invitation link about the session, covering various educational topics related to diabetes management. Additionally, after each session, patients will receive a brochure summarizing what has been discussed.",[18],"Behavioral: PharmaTE Trial",[20],{"type":21,"name":22,"description":16,"armGroupLabels":23,"otherNames":12},"BEHAVIORAL","PharmaTE Trial",[14],[25],{"name":26,"role":27,"phone":28,"phoneExt":12,"email":29},"Rabia Hussain, PhD, Lecturer","CONTACT","+60-46534085","rabia.hussain@usm.my",{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"SPONSOR_INVESTIGATOR","Rabia Hussain","DR. Rabia Hussain, Principal Investigator",[35],{"name":5,"class":6},"100596312","impact-of-pharmate-trial-on-glycemic-control-diabetes-knowledge-medication-adherence-and-quality-of-life-in-type-2-diabetes-patients-a-mixed-method-study-protocol-100596312",false,"NCT07043816","Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol","PharmaTE","Inclusion Criteria\n\n* Patients diagnosed with uncontrolled type 2 diabetes (defined as glycated haemoglobin \\[HbA1c\\] \\>7%) within the previous 12 months\n* Adults (18 to 65 years) of either gender\n* Prescribed at least one antidiabetic medication\n* Have access to either a telephone or a mobile phone\n* Treated in an outpatient facility in IBOH, RAK\n* Arabic-speaking patients\n* Patients who understand study information and are given written informed consent.\n\nExclusion Criteria:\n\n* Under 18 years old\n* Pregnant ladies\n* Patients admitted to the emergency department\n* Patients with severe hepatic or renal dysfunction\n* Diagnosed with type 1 DM or diagnosed with gestational diabetes\n* Having vision or hearing impairments and psychological problems\n* Immunocompromised patients, e.g., organ transplants, AIDS, cancer patients, and patients on immunosuppressant therapy\n* Patients with no or limited access to either a telephone or mobile phone, as well as those without reliable internet access","ALL","18 Years","65 Years",{"count":47,"type":48},154,"ESTIMATED","INTERVENTIONAL",[51],"NA","The goal of this clinical trial is to find out whether a pharmacist-led tele-educational program (PharmaTE trial) can help people with type 2 diabetes manage their condition better.\n\nThe main questions this study aims to answer are:\n\n1. Does the PharmaTE trial improve blood sugar control (HbA1c levels)?\n2. Does it help patients better understand their condition?\n3. Does it increase how well patients follow their medication schedule?\n4. Does it improve the quality of life for patients with type 2 diabetes?\n5. Is this type of tele-education program feasible and acceptable for patients?\n\nParticipants will:\n\nBe randomly placed into one of two groups:\n\nIntervention group: Receive five virtual education sessions with a clinical pharmacist over the phone or via Zoom (each lasting 20-30 minutes), in addition to their usual diabetes care.\n\nControl group: Continue receiving standard diabetes care from their healthcare team without the additional pharmacist-led sessions.\n\nComplete assessments at the beginning and end of the study. These include:\n\nA blood test for HbA1c\n\n, Questionnaires on diabetes knowledge, medication adherence, and quality of life\n\nSome participants in the intervention group will be invited for interviews after the sessions to share their experiences and opinions about the program.\n\nWho can join? Adults aged 18-65 with uncontrolled type 2 diabetes (HbA1c \\> 7%), receiving care at Ibrahim Bin Hamad Obaidullah Hospital in Ras Al-Khaimah, who speak Arabic and can provide consent.",[54,55,56,57,58],"Type 2 Diabetes (T2DM)","Glycemic Control","Diabetes Knowledge","Medication Adherence","Quality of Life",[41],"NOT_YET_RECRUITING","2026-04-28",{"date":63,"type":64},"2026-04-29","ACTUAL",{"date":66,"type":48},"2026-09-01",{"date":68,"type":48},"2027-12-31",{"name":32,"class":6}]